HIGHLIGHTS
- who: Helena Rouco et al. from the Faculty of, Universidade de Santiago de have published the research work: Rifabutin-Loaded Nanostructured Lipid Carriers as a Tool in Oral Anti-Mycobacterial Treatment of Crohn’s Disease, in the Journal: (JOURNAL)
- what: The aim of this work is focused on the in vitro evaluation of rifabutin (RFB)-loaded Nanostructured lipid carriers (NLC) to solve limitations associated to this therapeutic approach. Despite this information, CD's current treatment is still focused on the pharmacological control of the inflammatory process (using immunosuppressants, corticosteroids, anti-TNF or anti-interleukin drugs . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.